BHCM
BNTX icon

Brevan Howard Capital Management’s BioNTech BNTX Stock Holding History

Brevan Howard Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,000
Closed -$476K – 2164
2025
Q4 		$476K Sell
5,000
-2,064
-29% -$208K 0.01% 1140
2025
Q3 		$697K Buy
+7,064
New +$755K ﹤0.01% 1106

Other funds holding BNTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Brevan Howard Capital Management's BNTX Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of BioNTech (BNTX) in Q1 2026, closing a stake of 5,000 shares — an estimated $476K sold.

Brevan Howard Capital Management first reported a position in BNTX in Q3 2025 and held it in 2 quarters. The position peaked at $697K in Q3 2025. 272 funds tracked by Wall St. Rank hold BNTX as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining BioNTech position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 5,000 BioNTech shares in Q1 2026, an estimated $476K.
  • Brevan Howard Capital Management first reported a position in BioNTech in Q3 2025 and held it in 2 quarters.
  • Brevan Howard Capital Management's BioNTech position peaked at $697K in Q3 2025.
  • 272 funds tracked by Wall St. Rank held BioNTech as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.